Salarius Pharmaceuticals, Inc. (SLRX)
|52 Week Range||1.07-7.2|
|1y Target Est||-|
|DCF Unlevered||SLRX DCF ->|
|DCF Levered||SLRX LDCF ->|
|Debt / Equity||41.08%||Neutral|
Upgrades & Downgrades
Latest SLRX news
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of tre...
9 May 2023
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatme...
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conf...
4 April 2023
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer...
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugu...
19 January 2023
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conferenc...
19 October 2022
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer ...
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
20 September 2022
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of n...
Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcri...
8 August 2022
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations D...
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceutical...
2 August 2022
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to tre...
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conferenc...
29 July 2022
Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
18 May 2022
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript
12 May 2022
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Arthur - Chief Executive Of...
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >